Emerging drugs for chronic obstructive pulmonary disease

Bibliography

• Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442
   PubMed Web of Science ®Google Scholar
• Mannino DM. The natural history of chronic obstructive pulmonary disease. Pneumonol Alergol Pol 2011;79:139-43
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. Revised 2011. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011Dec30.pdf
   Google Scholar
• Gross NJ. The COPD pipeline. COPD 2010;7:154-6
   PubMedGoogle Scholar
• Cazzola M, Dahl R. Inhaled combination therapy with long-acting beta2-agonists and corticosteroids in stable COPD. Chest 2004;126:220-37
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004;1:264-8
   PubMedGoogle Scholar
• Calverley PMA, Anderson JA, Celli B, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Calverley PMA, Seemungal TA, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-54
   PubMed Web of Science ®Google Scholar
• Gross NJ. The COPD Pipeline X. COPD 2011;8:244-7
   PubMedGoogle Scholar
• Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
   PubMed Web of Science ®Google Scholar
• Kesler BS, Canning BJ. Regulation of baseline cholinergic tone in guinea-pig airway smooth muscle. J Physiol 1999;518:843-55
   PubMed Web of Science ®Google Scholar
• Racke K, Matthiesen S. The airway cholinergic system: physiology and pharmacology. Pulm Pharmacol Ther 2004;17:181-98
   PubMed Web of Science ®Google Scholar
• Racke K, Juergens UR, Matthiesen S. Control by cholinergic mechanisms. Eur J Pharmacol 2006;533:57-68
   PubMed Web of Science ®Google Scholar
• Coulson FR, Fryer AD. Muscarinic acetylcholine receptors and airway diseases. Pharmacol Ther 2003;98:59-69
   PubMed Web of Science ®Google Scholar
• Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005;2:297-304
   PubMedGoogle Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257-67
   PubMed Web of Science ®Google Scholar
• Sato E, Koyama S, Okubo Y, Acetylcholine stimulates alveolar macrophages to release inflammatory cell chemotactic activity. Am J Physiol 1998;274:L970-9
   PubMed Web of Science ®Google Scholar
• Profita M, Bonanno A, Siena L, Acetylcholine mediates the release of IL-8 in human bronchial epithelial cells by a NFkappaB/ERK-dependent mechanism. Eur J Pharmacol 2008;582:145-53
   PubMed Web of Science ®Google Scholar
• Buhling F, Lieder N, Kuhlmann UC, Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro. Respir Med 2007;101:2386-94
   PubMed Web of Science ®Google Scholar
• Gosens R, Rieks D, Meurs H, Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. Eur Respir J 2009;34:1436-43
   PubMed Web of Science ®Google Scholar
• Matthiesen S, Bahulayan A, Kempkens S, Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am J Respir Cell Mol Biol 2006;35:621-7
   PubMed Web of Science ®Google Scholar
• Gosens R, Dueck G, Rector E, Cooperative regulation of GSK-3 by muscarinic and PDGF receptors is associated with airway myocyte proliferation. Am J Physiol Lung Cell Mol Physiol 2007;293:L1348-58
   PubMed Web of Science ®Google Scholar
• Haag S, Matthiesen S, Juergens UR, Racke K. Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts. Eur Respir J 2008;32:555-6
   PubMed Web of Science ®Google Scholar
• van der Velden VH, Hulsmann AR. Autonomic innervation of human airways: structure, function, and pathophysiology in asthma. Neuroimmunomodulation 1999;6:145-59
   PubMed Web of Science ®Google Scholar
• Barnes PJ. beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995;152:838-60
   PubMed Web of Science ®Google Scholar
• Ruffin RE, McIntyre EL, Latimer KM, Assessment of beta-adrenoceptor antagonists in asthmatic patients. Br J Clin Pharmacol 1982;13(Suppl 2):325S-35S
   PubMedGoogle Scholar
• Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis 1985;132:541-7
   PubMed Web of Science ®Google Scholar
• Spina D, Rigby PJ, Paterson JW, Goldie RG. Autoradiographic localization of beta-adrenoceptors in asthmatic human lung. Am Rev Respir Dis 1989;140:1410-15
   PubMed Web of Science ®Google Scholar
• Canning BJ, Fischer A. Neural regulation of airway smooth muscle tone. Respir Physiol 2001;125:113-27
   PubMedGoogle Scholar
• Johnson M. The beta-adrenoceptor. Am J Respir Crit Care Med 1998;158:S146-53
   PubMed Web of Science ®Google Scholar
• Aizawa H, Inoue H, Ikeda T, Effects of procaterol, a beta-2-adrenoceptor stimulant, on neuroeffector transmission in human bronchial tissue. Respiration 1991;58:163-6
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Patel HJ, Takahashi T, Paradoxical facilitation of acetylcholine release from parasympathetic nerves innervating guinea-pig trachea by isoprenaline. Br J Pharmacol 1996;117:1413-20
   PubMed Web of Science ®Google Scholar
• Gu Q, Lee L-Y. Neural Control of Airway Smooth Muscle. Encyclopedia of Respiratory Medicine Elsevier: Amsterdam; 2006. p. 138-45
   Google Scholar
• Shah S, Page CP, Spina D. Nociceptin inhibits non-adrenergic non-cholinergic contraction in guinea-pig airway. Br J Pharmacol 1998;125:510-16
   PubMed Web of Science ®Google Scholar
• Said SI, Rattan S. The multiple mediators of neurogenic smooth muscle relaxation. Trends Endocrinol Metab 2004;15:189-91
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004;59:574-80
   PubMed Web of Science ®Google Scholar
• Spina D. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Drugs 2003;63:2575-94
   PubMed Web of Science ®Google Scholar
• Martorana PA, Beume R, Lucattelli M, Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke. Am J Respir Crit Care Med 2005;172:848-53
   PubMed Web of Science ®Google Scholar
• Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol 2004;25:33-9
   PubMed Web of Science ®Google Scholar
• Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70
   PubMed Web of Science ®Google Scholar
• Flamand N, Boudreault S, Picard S, Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am J Respir Crit Care Med 2000;161:S88-94
   PubMed Web of Science ®Google Scholar
• Cadieux JS, Leclerc P, St-Onge M, Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci 2005;118:1437-47
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003;22:672-88
   PubMed Web of Science ®Google Scholar
• Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2009;41:631-8
   PubMed Web of Science ®Google Scholar
• Geng JG. Directional migration of leukocytes: their pathological roles in inflammation and strategies for development of anti-inflammatory therapies. Cell Res 2001;11:85-8
   PubMed Web of Science ®Google Scholar
• Cheung LS, Raman PS, Balzer EM, Biophysics of selectin-ligand interactions in inflammation and cancer. Phys Biol 2011;8:015013
   PubMed Web of Science ®Google Scholar
• Riise GC, Larsson S, Lofdahl CG, Andersson BA. Circulating cell adhesion molecules in bronchial lavage and serum in COPD patients with chronic bronchitis. Eur Respir J 1994;7:1673-7
   PubMed Web of Science ®Google Scholar
• Schumacher A, Liebers U, John M, P-selectin glycoprotein ligand-1 (PSGL-1) is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease. Clin Exp Immunol 2005;142:370-6
   PubMed Web of Science ®Google Scholar
• Di Stefano A, Maestrelli P, Roggeri A, Upregulation of adhesion molecules in the bronchial mucosa of subjects with chronic obstructive bronchitis. Am J Respir Crit Care Med 1994;149:803-10
   PubMed Web of Science ®Google Scholar
• Barnes PJ. COPD: is there light at the end of the tunnel? Curr Opin Pharmacol 2004;4:263-72
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Cazzola M. TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water. Pulm Pharmacol Ther 2010;23:121-8
   PubMed Web of Science ®Google Scholar
• Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003;63:1973-98
   PubMed Web of Science ®Google Scholar
• Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002;109:S81-96
   PubMed Web of Science ®Google Scholar
• Edwards MR, Bartlett NW, Clarke D, Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009;121:1-13
   PubMed Web of Science ®Google Scholar
• Pelaia G, Cuda G, Vatrella A, Mitogen-activated protein kinases and asthma. J Cell Physiol 2005;202:642-53
   PubMed Web of Science ®Google Scholar
• Renda T, Baraldo S, Pelaia G, Increased activation of p38 MAPK in COPD. Eur Respir J 2008;31:62-9
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006;109:238-45
   PubMed Web of Science ®Google Scholar
• Shieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005;5:921-8
   PubMed Web of Science ®Google Scholar
• Clark AR, Dean JL, Saklatvala J. Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003;546:37-44
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7
   PubMed Web of Science ®Google Scholar
• Ghigo A, Damilano F, Braccini L, Hirsch E. PI3K inhibition in inflammation: toward tailored therapies for specific diseases. Bioessays 2010;32:185-96
   PubMed Web of Science ®Google Scholar
• Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010;4:19-34
   PubMedGoogle Scholar
• Sapey E, Stockley JA, Greenwood H, Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:1176-86
   PubMed Web of Science ®Google Scholar
• Crooks SW, Stockley RA. Leukotriene B4.. Int J Biochem Cell Biol 1998;30:173-8
   PubMed Web of Science ®Google Scholar
• Hicks A, Monkarsh SP, Hoffman AF, Goodnow R Jr. Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opin Investig Drugs 2007;16:1909-20
   PubMed Web of Science ®Google Scholar
• Profita M, Sala A, Riccobono L, 15(S)-HETE modulates LTB4 production and neutrophil chemotaxis in chronic bronchitis. Am J Physiol Cell Physiol 2000;279:C1249-58
   PubMed Web of Science ®Google Scholar
• Devchand PR, Keller H, Peters JM, The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996;384:39-43
   PubMed Web of Science ®Google Scholar
• Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005;51:85-94
   PubMed Web of Science ®Google Scholar
• Van Bilsen M, Van Nieuwenhoven FA. PPARs as therapeutic targets in cardiovascular disease. Expert Opin Ther Targets 2010;14:1029-45
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Mitchell JA. Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease. Br J Pharmacol 2009;158:994-1003
   PubMed Web of Science ®Google Scholar
• Narala VR, Adapala RK, Suresh MV, Leukotriene B4 is a physiologically relevant endogenous peroxisome proliferator-activated receptor-alpha agonist. J Biol Chem 2010;285:22067-74
   PubMed Web of Science ®Google Scholar
• Groutas WC, Dou D, Alliston KR. Neutrophil elastase inhibitors. Expert Opin Ther Pat 2011;21:339-54
   PubMed Web of Science ®Google Scholar
• Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010;46:139-50
   PubMed Web of Science ®Google Scholar
• Jones PW, Barnes N, Vogelmeier C, Efficacy of indacaterol in the treatment of patients with COPD. Prim Care Respir J 2011;20:380-8
   PubMedGoogle Scholar
• Bouyssou T, Casarosa P, Naline E, Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010;334:53-62
   PubMed Web of Science ®Google Scholar
• van Noord JA, Smeets JJ, Drenth BM, 24-hour bronchodilation following a single dose of the novel beta2-agonist olodaterol in COPD. Pulm Pharmacol Ther 2011;24:666-72
   PubMed Web of Science ®Google Scholar
• Morrison V, Sturton G, Barrett V, Pharmacological characterisation of GW642444, a long-acting beta2-agonist (LABA) with rapid onset and long duration, on isolated large and small human airways [abstract]. Am J Respir Crit Care Med 2010;181:A4453
   Web of Science ®Google Scholar
• Ford A, Hughes S, Morrison V, In vitro and in vivo pharmacological characterisation of GW642444, a novel long-acting beta2 agonist (LABA), with fast onset and long duration in the guinea-pig [abstract]. Am J Respir Crit Care Med 2010;181:A5677
   Google Scholar
• Barrett V, Emmons A, Ford A, Knowles R. In vitro pharmacological characterisation of GW642444, a novel long acting beta2-agonist (LABA) using human recombinant beta1/2/3 adrenoceptor cAMP assays [abstract]. Am J Respir Crit Care Med 2010;181:A4451
   Web of Science ®Google Scholar
• Hanania NA, Feldman G, Zachgo W, The efficacy and safety of the novel long-acting beta2 agonist vilanterol in COPD patients: a randomized placebo-controlled trial. Chest 2012; doi:10.1378/chest.11-2231
   PubMedGoogle Scholar
• Aparici M, Gomez-Angelats M, Vilella D, The in vitro pharmacological profile of LAS100977 – a potent, selective and long-acting beta-2 receptor agonist [abstract]. Am J Respir Crit Care Med 2010;181:A5675
   Google Scholar
• Glossop PA, Lane CA, Price DA, Inhalation by design: novel ultra-long-acting beta2-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem 2010;53:6640-52
   PubMed Web of Science ®Google Scholar
• Young A, Nicholls D, Connolly S, Azd3199: a potent and selective beta2-adrenergic receptor agonist with rapid onset of action [abstract]. Am J Respir Crit Care Med 2011;183:A1585
   Google Scholar
• Kuna P, Ivanov Y, Trofimov V, Efficacy and safety of AZD3199, an inhaled ultra long-acting beta2-agonist, in patients with COPD [abstract]. Eur Respir J 2011;38:148s
   Google Scholar
• Villetti G, Bergamaschi M, Bassani F, Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br J Pharmacol 2006;148:291-8
   PubMed Web of Science ®Google Scholar
• Verkindre C, Fukuchi Y, Flemale A, Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104:1482-9
   PubMed Web of Science ®Google Scholar
• Fogarty C, Hattersley H, Di Scala L, Drollmann A. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2011;105:337-42
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Ferguson GT, van Noord JA, Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res 2011;12:156
   PubMed Web of Science ®Google Scholar
• Gavalda A, Miralpeix M, Ramos I, Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 2009;331:740-51
   PubMed Web of Science ®Google Scholar
• Cazzola M. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD. Curr Opin Investig Drugs 2009;10:482-90
   PubMed Web of Science ®Google Scholar
• Fuhr R, Magnussen H, Sarem K, Efficacy of aclidinium bromide 400 mug BID compared with placebo and tiotropium in patients with moderate-to-severe COPD. Chest 2011; doi 10.1378/chest.11-0406
   PubMed Web of Science ®Google Scholar
• Jones PW, Agusti A, Bateman ED, Aclidinium bromide in patients with chronic obstructive pulmonary disease: efficacy and safety results from ATTAIN [abstract]. Am J Respir Crit Care Med 2011;183:A6350
   Google Scholar
• Laine DI, Luttmann MA, Foley JJ, The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing [abstract]. Eur Respir J 2011;38:613s
   Google Scholar
• Decramer M, Maltais F, Feldman G, Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD [abstract]. Eur Respir J 2011;38:150s
   Google Scholar
• Mehta R, Newlands A, Kelleher D, Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD [abstract]. Eur Respir J 2011;38:138s
   Google Scholar
• Villetti G, Pastore F, Bergamaschi M, Bronchodilator activity of (3R)-3-[[[(3-fluorophenyl)[(3,4,5-trifluorophenyl)methyl]amino] carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane bromide (CHF5407), a potent, long-acting, and selective muscarinic M3 receptor antagonist. J Pharmacol Exp Ther 2010;335:622-35
   PubMed Web of Science ®Google Scholar
• Patel S, Marshall S, Summerhilll S, The in-vitro pharmacology of PF-4522971 – A novel inhaled muscarinic M3 antagonist [abstract]. Eur Respir J 2010;36:219s
   Google Scholar
• Page CP. Doxofylline: a “novofylline”. Pulm Pharmacol Ther 2010;23:231-4
   PubMed Web of Science ®Google Scholar
• van Mastbergen J, Jolas T, Allegra L, Page CP. The mechanism of action of doxofylline is unrelated to HDAC inhibition, PDE inhibition or adenosine receptor antagonism. Pulm Pharmacol Ther 2012;25:55-61
   PubMed Web of Science ®Google Scholar
• Billington CK, Le Jeune IR, Young KW, Hall IP. A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2008;38:1-7
   PubMed Web of Science ®Google Scholar
• Schmidt DT, Watson N, Dent G, The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways. Br J Pharmacol 2000;131:1607-18
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009;374:685-94
   PubMed Web of Science ®Google Scholar
• Celli B. COPD, inflammation and its modulation by phosphodiesterase 4 inhibitors: time to look beyond the FEV1. Chest 2006;129:5-6
   PubMed Web of Science ®Google Scholar
• Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol 2006;117:1237-43
   PubMed Web of Science ®Google Scholar
• Banner KH, Press NJ. Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease. Br J Pharmacol 2009;157:892-906
   PubMed Web of Science ®Google Scholar
• Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010;19:330-8
   PubMed Web of Science ®Google Scholar
• Bradding P, Wulff H. The K+ channels KCa3.1 and Kv1.3 as novel targets for asthma therapy. Br J Pharmacol 2009;157:1330-9
   PubMed Web of Science ®Google Scholar
• Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res 2011;12:45
   PubMedGoogle Scholar
• Fernandes LB, Henry PJ, Goldie RG. Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease. Ther Adv Respir Dis 2007;1:25-33
   PubMedGoogle Scholar
• Gosens R, Schaafsma D, Meurs H, Role of Rho-kinase in maintaining airway smooth muscle contractile phenotype. Eur J Pharmacol 2004;483:71-8
   PubMed Web of Science ®Google Scholar
• Hamad AM, Range S, Holland E, Knox AJ. Regulation of cGMP by soluble and particulate guanylyl cyclases in cultured human airway smooth muscle. Am J Physiol 1997;273:L807-13
   PubMed Web of Science ®Google Scholar
• Hamad AM, Clayton A, Islam B, Knox AJ. Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Am J Physiol Lung Cell Mol Physiol 2003;285:L973-83
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Parascandolo V, Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi. Pulm Pharmacol Ther 2009;22:478-82
   PubMed Web of Science ®Google Scholar
• Matera MG, Calzetta L, Passeri D, Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi. Br J Pharmacol 2011;163:1740-54
   PubMed Web of Science ®Google Scholar
• Redington AE. Modulation of nitric oxide pathways: therapeutic potential in asthma and chronic obstructive pulmonary disease. Eur J Pharmacol 2006;533:263-76
   PubMed Web of Science ®Google Scholar
• Lagente V, Naline E, Guenon I, A nitric oxide-releasing salbutamol elicits potent relaxant and anti-inflammatory activities. J Pharmacol Exp Ther 2004;310:367-75
   PubMed Web of Science ®Google Scholar
• Castro PF, Pereira Ade C, Rogrigues GJ, A new nitrosyl ruthenium complex nitric oxide donor presents higher efficacy than sodium nitroprusside on relaxation of airway smooth muscle. Eur J Pharm Sci 2011;43:370-7
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Uchiyama K, Irie T, Murao M. Evaluation of aerosols of prostaglandins E1 and E2 as bronchodilators. Eur J Clin Pharmacol 1973;6:127-32
   PubMed Web of Science ®Google Scholar
• Buckley J, Birrell MA, Maher SA, EP4 receptor as a new target for bronchodilator therapy. Thorax 2011;66:1029-35
   PubMed Web of Science ®Google Scholar
• Deshpande DA, Wang WCH, McIlmoyle EL, Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction. Nat Med 2010;16:1299-304
   PubMed Web of Science ®Google Scholar
• Robinett KS, Deshpande DA, Malone MM, Liggett SB. Agonist-promoted homologous desensitization of human airway smooth muscle bitter taste receptors. Am J Respir Cell Mol Biol 2011;45:1069-74
   PubMed Web of Science ®Google Scholar
• Doggrell SA. Bitter taste receptors as a target for bronchodilation. Expert Opin Ther Targets 2011;15:899-902
   PubMed Web of Science ®Google Scholar
• Diamant Z, Spina D. PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease. Pulm Pharmacol Ther 2011;24:353-60
   PubMed Web of Science ®Google Scholar
• Danto S, Wei GC, Gill J. A randomized, double-blind, placebo-controlled, parallel group, six-week study of the efficacy and safety of tofimilast dry powder for inhalation (DPI) in adults with COPD [abstract]. Am J Respir Crit Care Med 2007;175:A131
   Google Scholar
• Gutke HJ, Guse JH, Khobzaoui M, AWD-12-281(inhaled) (elbion/GlaxoSmithKline). Curr Opin Investig Drugs 2005;6:1149-58
   PubMedGoogle Scholar
• Vestbo J, Tan L, Atkinson G, Ward J. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J 2009;33:1039-44
   PubMed Web of Science ®Google Scholar
• Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009;18:1505-17
   PubMed Web of Science ®Google Scholar
• Luijk B, van den Berge M, Kerstjens HA, Effect of an inhaled adenosine A2A agonist on the allergen-induced late asthmatic response. Allergy 2008;63:75-80
   PubMed Web of Science ®Google Scholar
• Trevethick MA, Mantell SJ, Stuart EF, Treating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutions. Br J Pharmacol 2008;155:463-74
   PubMed Web of Science ®Google Scholar
• Impellizzeri D, Di Paola R, Esposito E, CGS 21680, an agonist of the adenosine (A2A) receptor, decreases acute lung inflammation. Eur J Pharmacol 2011;668:305-16
   PubMed Web of Science ®Google Scholar
• Wallace KL, Linden J. Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood 2010;116:5010-20
   PubMed Web of Science ®Google Scholar
• Brown RA, Spina D, Page CP. Adenosine receptors and asthma. Br J Pharmacol 2008;153(Suppl 1):S446-56
   PubMed Web of Science ®Google Scholar
• Thomas GS, Tammelin BR, Schiffman GL, Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008;15:319-28
   PubMed Web of Science ®Google Scholar
• Samsel M, Dzierzbicka K. Therapeutic potential of adenosine analogues and conjugates. Pharmacol Rep 2011;63:601-17
   PubMed Web of Science ®Google Scholar
• Davenpeck KL, Berens KL, Dixon RA, Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: preferential activity against neutrophil adhesion in vitro. J Allergy Clin Immunol 2000;105:769-75
   PubMed Web of Science ®Google Scholar
• Radi ZA, Caverly JM, Dixon RA, Effects of the synthetic selectin inhibitor TBC1269 on tissue damage during acute Mannheimia haemolytica-induced pneumonia in neonatal calves. Am J Vet Res 2001;62:17-22
   PubMed Web of Science ®Google Scholar
• Bock D, Beeh K, Beier J, Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD [abstract]. Eur Respir J 2007;30:613s
   PubMedGoogle Scholar
• Bedard PW, Kaila N. Selectin inhibitors: a patent review. Expert Opin Ther Patent 2010;20:781-93
   PubMed Web of Science ®Google Scholar
• Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008;21:234-8
   PubMed Web of Science ®Google Scholar
• Donnelly LE, Rogers DF. Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs 2003;63:1973-98
   PubMed Web of Science ®Google Scholar
• Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest 2004;126:926-34
   PubMed Web of Science ®Google Scholar
• Chapman RW, Minnicozzi M, Celly CS, A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322:486-93
   PubMed Web of Science ®Google Scholar
• D'Elios MM, Prete GD, Amedei A. Interfering with chemokines and chemokine receptors as potential new therapeutic strategies. Expert Opin Ther Patents 2008;18:309-25
   Web of Science ®Google Scholar
• Holz O, Khalilieh S, Ludwig-Sengpiel A, SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010;35:564-70
   PubMed Web of Science ®Google Scholar
• Lazaar AL, Sweeney LE, MacDonald AJ, SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 2011;72:282-93
   PubMed Web of Science ®Google Scholar
• Pease JE, Sabroe I. The role of interleukin-8 and its receptors in inflammatory lung disease: implications for therapy. Am J Respir Med 2002;1:19-25
   PubMedGoogle Scholar
• Owen C. Chemokine receptors in airway disease: which receptors to target? Pulm Pharmacol Ther 2001;14:193-202
   PubMed Web of Science ®Google Scholar
• Xia M, Sui Z. Recent developments in CCR2 antagonists. Expert Opin Ther Patent 2009;19:295-303
   PubMed Web of Science ®Google Scholar
• Saetta M, Mariani M, Panina-Bordignon P, Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;165:1404-9
   PubMed Web of Science ®Google Scholar
• Zhang J, Patel JM. Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases. Int J Clin Expert Med 2010;3:233-44
   PubMedGoogle Scholar
• Ning W, Li CJ, Kaminski N, Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. Proc Natl Acad Sci USA 2004;101:14895-900
   PubMed Web of Science ®Google Scholar
• Dorgham K, Ghadiri A, Hermand P, An engineered CX3CR1 antagonist endowed with anti-inflammatory activity. J Leukoc Biol 2009;86:903-11
   PubMed Web of Science ®Google Scholar
• Suzuki J, Ogawa M, Muto S, Novel IkB kinase inhibitors for treatment of nuclear factor-kB-related diseases. Expert Opin Investig Drugs 2011;20:395-405
   PubMed Web of Science ®Google Scholar
• Keslacy S, Tliba O, Baidouri H, Amrani Y. Inhibition of tumor necrosis factor-alpha-inducible inflammatory genes by interferon-gamma is associated with altered nuclear factor-kappaB transactivation and enhanced histone deacetylase activity. Mol Pharmacol 2007;71:609-18
   PubMed Web of Science ®Google Scholar
• Catley MC, Sukkar MB, Chung KF, Validation of the anti-inflammatory properties of small-molecule IkappaB Kinase (IKK)-2 inhibitors by comparison with adenoviral-mediated delivery of dominant-negative IKK1 and IKK2 in human airways smooth muscle. Mol Pharmacol 2006;70:697-705
   PubMed Web of Science ®Google Scholar
• Gill JS, Zhu X, Moore MJ, Effects of NFkappaB decoy oligonucleotides released from biodegradable polymer microparticles on a glioblastoma cell line. Biomaterials 2002;23:2773-81
   PubMed Web of Science ®Google Scholar
• Seguin RM, Ferrari N. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009;18:1505-17
   PubMed Web of Science ®Google Scholar
• Pettus LH, Wurz RP. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008. Curr Top Med Chem 2008;8:1452-67
   PubMed Web of Science ®Google Scholar
• Underwood DC, Osborn RR, Kotzer CJ, SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Expert Ther 2000;293:281-8
   PubMed Web of Science ®Google Scholar
• Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 2011;139:1470-9
   PubMed Web of Science ®Google Scholar
• Branger J, van den Blink B, Weijer S, Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002;168:4070-7
   PubMed Web of Science ®Google Scholar
• Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007;28:286-95
   PubMed Web of Science ®Google Scholar
• Tan E, Jones I, Tweedy S, The novel oral p38 inhibitor, PH-797804, inhibits inhaled lipopolysaccharide (LPS)-induced airway and systemic inflammatory markers in healthy subjects [abstract]. Am J Respir Crit Care Med 2011;183:A2554
   Google Scholar
• MacNee W, Allan R, Jones I, A randomised, placebo controlled trial of 6 weeks' treatment with a novel oral p38 inhibitor in patients with COPD [abstract]. Eur Respir J 2010;36(Suppl 54):718s
   PubMedGoogle Scholar
• Barnes NB, Pavord IP, Maden CM, Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD [abstract]. Eur Respir J 2009;34(Suppl 53):648s
   PubMed Web of Science ®Google Scholar
• Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008;17:1411-25
   PubMed Web of Science ®Google Scholar
• Millan DS, Bunnage ME, Burrows JL, Design and synthesis of inhaled p38 inhibitors for the treatment of Chronic Obstructive Pulmonary disease. J Med Chem 2011;54:7797-814
   PubMed Web of Science ®Google Scholar
• Matera MG, Cazzola M. New anti-inflammatory approaches in COPD. Drug Discov Today 2004;1:335-43
   Google Scholar
• Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009;21:317-24
   PubMed Web of Science ®Google Scholar
• Duraisamy S, Bajpai M, Bughani U, MK2: a novel molecular target for anti-inflammatory therapy. Expert Opin Ther Targets 2008;12:921-36
   PubMed Web of Science ®Google Scholar
• Doukas J, Eide L, Stebbins K, Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009;328:758-65
   PubMed Web of Science ®Google Scholar
• Reutershan J, Saprito MS, Wu D, Phosphoinositide-3 kinase gamma required for LPS-induced transepithelial neutrophil trafficking in the lung. Eur Respir J 2010;35:1137-47
   PubMed Web of Science ®Google Scholar
• Tudhope SJ, Finney-Hayward TK, Nicholson AG, Different mitogen-activated protein kinase-dependent cytokine responses in cells of the monocyte lineage. J Pharmacol Exp Ther 2008;324:306-12
   PubMed Web of Science ®Google Scholar
• Maus UA, Backi M, Winter C, Importance of phosphoinositide 3-kinase gamma in the host defense against pneumococcal infection. Am J Respir Crit Care Med 2007;175:958-66
   PubMed Web of Science ®Google Scholar
• Hicks A, Goodnow R Jr, Cavallo G, Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates. Prostaglandins Other Lipid Mediat 2010;92:33-43
   PubMed Web of Science ®Google Scholar
• Gronke L, Beeh KM, Cameron R, Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008;21:409-17
   PubMed Web of Science ®Google Scholar
• Gompertz S, Stockley RA. A randomized, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest 2002;122:289-94
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Liu N, Knorr BA, MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease. Respir Med 2011;105:392-401
   PubMed Web of Science ®Google Scholar
• Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006;533:101-9
   PubMed Web of Science ®Google Scholar
• Velayudhan J, Haran AC, Wright CD. The non-thiazolidinedione PPAR-Gamma ligand, GW1929 displays anti-inflammatory activity in poly(I: C)-induced air-liquid interface human bronchial epithelial cells [abstract]. Am J Respir Crit Care Med 2011;183:A2827
   Google Scholar
• Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85
   PubMed Web of Science ®Google Scholar
• Murphy DM, Forrest IA, Curran D, Ward C. Macrolide antibiotics and the airway: antibiotic or non-antibiotic effects? Expert Opin Investig Drugs 2010;19:401-14
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG, Blasi F. Macrolide and occult infection in asthma. Curr Opin Pulm Med 2004;10:7-14
   PubMed Web of Science ®Google Scholar
• Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respiration 2011;81:67-74
   PubMed Web of Science ®Google Scholar
• Nakanishi Y, Kobayashi D, Asano Y, Clarithromycin prevents smoke-induced emphysema in mice. Am J Respir Crit Care Med 2009;179:271-8
   PubMed Web of Science ®Google Scholar
• Jang YJ, Kwon HJ, Lee BJ. Effect of clarithromycin on rhinovirus-16 infection in A549 cells. Eur Respir J 2006;27:12-19
   PubMed Web of Science ®Google Scholar
• Tsai WC, Rodriguez ML, Young KS, Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am J Respir Crit Care Med 2004;170:1331-9
   PubMed Web of Science ®Google Scholar
• Marjanovic N, Bosnar M, Michielin F, Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol Res 2011;63:389-97
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Wilkinson TM, Hurst JR, Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98
   PubMed Web of Science ®Google Scholar
• Fecik RA, Nguyen PL, Venkatraman L. Approaches to the synthesis of immunolides: selective immunomodulatory macrolides for cystic fibrosis. Curr Opin Drug Discov Devel 2005;8:741-7
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sunazuka T, Nagai K, Macrolides with promotive activity of monocyte to macrophage differentiation. J Antibiot (Tokyo) 2005;58:79-81
   PubMed Web of Science ®Google Scholar
• Sugawara A, Sueki A, Hirose T, Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents. Bioorg Med Chem Lett 2011;21:3373-6
   PubMed Web of Science ®Google Scholar
• Mencarelli A, Distrutti E, Renga B, Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis. Eur J Pharmacol 2011;665:29-39
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Rossios C, Barnes PJ, Ito K. Superior anti-inflammatory effects of a novel macrolide/fluoroketolide, CEM-101, In monocytic cells [abstract]. Am J Respir Crit Care Med 2010;181:A4426
   Google Scholar
• Charron C, Sumakuza T, Oomura S, Ito K. EM-703, a non-antibacterial erythromycin derivative, restores HDAC2 activition diminished by hypoxia and oxidative stress [abstract]. Proc Am Thorac Soc 2007;175:A640
   Google Scholar
• Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J 2010;74:818-26
   PubMed Web of Science ®Google Scholar
• Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax 2006;61:729-34
   PubMed Web of Science ®Google Scholar
• Bonetti PO, Lerman LO, Napoli C, Lerman A. Statin effects beyond lipid lowering–are they clinically relevant? Eur Heart J 2003;24:225-48
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins R, Eaton TE. Pharmacological actions of statins: potential utility in COPD. Eur Respir Rev 2009;18:222-32
   PubMedGoogle Scholar
• Wright JL, Zhou S, Preobrazhenska O, Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011;183:50-8
   PubMed Web of Science ®Google Scholar
• Keddissi JI, Younis WG, Chbeir EA, The use of statins and lung function in current and former smokers. Chest 2007;132:1764-71
   PubMed Web of Science ®Google Scholar
• Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med 2009;9:32
   PubMedGoogle Scholar
• Djekic UV, Gaggar A, Weathington NM. Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther 2009;121:132-46
   PubMed Web of Science ®Google Scholar
• Kelly E, Greene CM, McElvaney NG. Targeting neutrophil elastase in cystic Expert Opin Ther Targets. 2008;12:145-57
   Google Scholar
• Ohnishi S, Nagaya N. Tissue regeneration as next-generation therapy for COPD - potential applications. Int J Chron Obstruct Pulmonol Dis 2008;3:509-14
   PubMedGoogle Scholar
• Hind M, Maden M. Is a regenerative approach viable for the treatment of COPD? Br J Pharmacol 2011;163:106-15
   PubMed Web of Science ®Google Scholar
• Stinchcombe SV, Maden M. Retinoic acid induced alveolar regeneration: critical differences in strain sensitivity. Am J Respir Cell Mol Biol 2008;38:185-91
   PubMed Web of Science ®Google Scholar
• Roth MD, Connett JE, D'Armiento JM, Feasibility of retinoids for the treatment of emphysema study. Chest 2006;130:1334-45
   PubMed Web of Science ®Google Scholar
• Stolk J, Cooper BG, Stoel B, Retinoid treatment of emphysema in patients on the alpha-1 international registry. The REPAIR study: study design methodology and quality control of study assessments. Ther Adv Respir Dis 2010;4:319-32
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Matera MG. β2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011;163:4-17
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009;374:695-703
   PubMed Web of Science ®Google Scholar
• Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir J 2009;34:757-69
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD006826
   PubMed Web of Science ®Google Scholar
• Nannini LJ, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2007;4:CD006829
   PubMed Web of Science ®Google Scholar
• Barrett EG. A novel mutual prodrug of salmeterol and desisobutrylciclesonide attenuates acute bronchoconstriction in the absence of cardiovascular side-effects in ragweed sensitized and naive dogs [abstract]. Am J Respir Crit Care Med 2010;181:A4249
   Google Scholar
• Barnes PJ. Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010;120:76-85
   PubMed Web of Science ®Google Scholar
• Cosio BG, Tsaprouni L, Ito K, Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-95
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Targeting the epigenome in the treatment of asthma and chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:693-6
   PubMedGoogle Scholar
• Biswas S, Rahman I. Modulation of steroid activity in chronic inflammation: a novel anti-inflammatory role for curcumin. Mol Nutr Food Res 2008;52:987-94
   PubMed Web of Science ®Google Scholar
• Nobili S, Landini I, Giglioni B, Mini E. Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 2006;7:861-79
   PubMed Web of Science ®Google Scholar
• Webster JI, Carlstedt-Duke J. Involvement of multidrug resistance proteins (MDR) in the modulation of glucocorticoid response. J Steroid Biochem Mol Biol 2002;82:277-88
   PubMed Web of Science ®Google Scholar
• Hoi AY, Iskander MN, Morand EF. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets 2007;6:183-90
   PubMedGoogle Scholar
• Vassilakopoulos T, Roussos C, Zakynthinos S. Is loaded breathing an inflammatory stimulus? Curr Opin Crit Care 2005;11:1-9
   PubMed Web of Science ®Google Scholar
• Suzuki J, Suzuki S, Okubo T. Effects of fenoterol on inspiratory effort sensation and fatigue during inspiratory threshold loading. J Appl Physiol 1996;80:727-33
   PubMed Web of Science ®Google Scholar
• Hatipoglu U, Laghi F, Tobin MJ. Does inhaled albuterol improve diaphragmatic contractility in patients with chronic obstructive pulmonary disease? Am J Respir Crit Care Med 1999;160:1916-21
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Fluge T, Gerken F, Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40
   PubMed Web of Science ®Google Scholar
• Powrie DJ, Wilkinson TM, Donaldson GC, Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007;30:472-8
   PubMed Web of Science ®Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008;134:1278-86
   PubMed Web of Science ®Google Scholar
• Kessler R, Partridge MR, Miravitlles M, Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
   PubMed Web of Science ®Google Scholar